Efavirenz to Nevirapine Switch in HIV-1-Infected Patients with Dyslipidemia: A Randomized, Controlled Study | Zendy

JeanJacques Parienti | Zendy; V. Massari | Zendy; D. Rey | Zendy; P. Poubeau | Zendy; Renaud Verdon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efavirenz to Nevirapine Switch in HIV-1-Infected Patients with Dyslipidemia: A Randomized, Controlled Study

Author(s) -

JeanJacques Parienti,

V. Massari,

D. Rey,

P. Poubeau,

Renaud Verdon

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/518973

Subject(s) - nevirapine , efavirenz , medicine , dyslipidemia , virology , human immunodeficiency virus (hiv) , reverse transcriptase inhibitor , randomized controlled trial , antiretroviral therapy , viral load , obesity

Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P<.04). A switch to nevirapine was associated with no severe adverse events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research